Autolus Therapeutics (AUTL) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUTL shares.
View AUTL analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month target prices for Autolus Therapeutics' shares. Their AUTL share price forecasts range from $5.00 to $12.00. On average, they predict the company's stock price to reach $8.20 in the next year. This suggests a possible upside of 180.8% from the stock's current price.
View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts.

Autolus Therapeutics' stock was trading at $1.90 at the start of the year. Since then, AUTL shares have increased by 53.7% and is now trading at $2.92.
View the best growth stocks for 2023 here.

Autolus Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 739,700 shares, a decline of 14.1% from the April 30th total of 861,000 shares. Based on an average trading volume of 573,600 shares, the short-interest ratio is presently 1.3 days.
View Autolus Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AUTL earnings forecast.

Autolus Therapeutics plc (NASDAQ:AUTL) announced its earnings results on Thursday, May, 4th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. The firm had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.09 million.

ETFs with the largest weight of Autolus Therapeutics (NASDAQ:AUTL) stock in their portfolio include Harbor Disruptive Innovation ETF (INNO).iShares Biotechnology ETF (IBB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD).

(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (5.59%), Perpetual Ltd (1.07%), BlackRock Inc. (0.51%), JPMorgan Chase & Co. (0.25%), MAI Capital Management (0.25%) and ExodusPoint Capital Management LP (0.24%).

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUTL stock can currently be purchased for approximately $2.92.

Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $505.36 million and generates $6.36 million in revenue each year. The company earns $-148,840,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

The company employs 324 workers across the globe.

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com.